Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53
A Second Controversial Duchenne Approval For Company
The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.
The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.